TEST:

Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody

A total of 100% (2/2) of desmoplastic melanomas and 50% (4/8) of nodular melanomas were PRAME positive. PRAME is a sensitive and highly specific immunostain in the diagnosis of in situ and invasive melanoma and we emphasize its application in the evaluation of high CSD and acral melanoma subtypes as well as in challenging threshold cases.

In this limited study, PRAME is expressed in 100% of PEComas demonstrating its utility as an additional IHC marker of melanocytic expression in this difficult tumor type. While PRAME expression was similar to HMB45 in most cases, it was stronger and more diffuse in two cases (33.3%). Additional testing to determine the expression of PRAME in tumors in the differential diagnosis with PEComas is underway.

Digital evaluation of Ki-67 appears to play an independent role in the progression of UM. This objective method is a promising tool for better prognostic stratification of UM patients.

"Roche...announced the launch of Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody to identify PRAME protein expression in tissue samples from patients with suspected melanoma. Because the PRAME (PReferentially expressed Antigen in MElanoma) protein is expressed in most melanomas, the PRAME (EPR20330) Antibody* is used as an aid to differentiate between benign and malignant lesions to help improve diagnostic decisions. If PRAME expression is detected, this suggests that the lesion is malignant."